In the context of indefinite venetoclax monotherapy for R/R CLL, the clinicopathological factors associated with inferior PFS on multivariate analysis include disease bulk (≥ 5 cm), BCRi or fludarabine refractoriness, TP53 aberrations and NOTCH1 mutations [44]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.